• Monomethyl Auristatin E: Precision Payloads for Tumor Plasti

  2026-04-30

  Explore how Monomethyl auristatin E (MMAE) is redefining antibody-drug conjugate payload strategy for challenging, plastic tumors. This piece blends mechanistic insights on tubulin polymerization inhibition with strategic, evidence-based guidance for translational researchers, referencing recent advances in differentiation therapy and cancer cell plasticity.

• MitMAB in Organoid Models: Elevating Endocytosis Research

  2026-04-30

  This thought-leadership article examines how MitMAB (N,N,N-trimethyltetradecan-1-aminium bromide), a potent dynamin GTPase inhibitor from APExBIO, is redefining mechanistic studies of endocytosis and membrane trafficking in physiologically relevant organoid systems. By synthesizing recent advances in extracellular vesicle (EV) uptake, benchmarking MitMAB against alternatives, and offering actionable protocol guidance, we chart a strategic roadmap for translational researchers seeking to bridge mechanistic insight with clinical relevance.

• Arctigenin Attenuates Doxorubicin Cardiotoxicity via KEAP1-N

  2026-04-29

  This study identifies arctigenin, a natural compound from Arctium lappa L., as a novel KEAP1-NRF2 pathway inhibitor that effectively protects against doxorubicin-induced cardiotoxicity. Integrating high-throughput screening with mechanistic and in vivo validation, the research demonstrates arctigenin’s potential as a cardioprotective agent and advances the search for alternatives to dexrazoxane.

• Bay 11-7821: Precision NF-κB Pathway Inhibition for Cancer a

  2026-04-29

  Bay 11-7821 (BAY 11-7082) empowers researchers to dissect NF-κB-driven signaling and apoptosis with unmatched selectivity, enabling robust exploration of immune resistance mechanisms and tumor microenvironment dynamics. This article translates the latest experimental insights into actionable workflows, highlighting APExBIO’s role in driving reproducible, high-impact studies.

• Afatinib (BIBW 2992): Advancing Tumor-Stroma Research Models

  2026-04-28

  Afatinib (BIBW 2992) revolutionizes cancer biology research through irreversible ErbB family inhibition, enabling high-fidelity tumor-stroma interaction studies in assembloid systems. This article translates recent reference breakthroughs into actionable workflows and expert troubleshooting, positioning APExBIO's Afatinib as an indispensable tool for targeted therapy research.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-04-28

  This study elucidates how Epstein-Barr virus (EBV) triggers dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma (NPC) via CEBPA repression, orchestrated by the LMP1/STAT5A/HDAC1/2 axis. Critically, it demonstrates that HDAC inhibitors can restore differentiation in NPC models, providing a mechanistic rationale for epigenetic differentiation therapy in solid tumors.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-04-27

  5-(N,N-dimethyl)-Amiloride hydrochloride delivers unmatched precision for dissecting Na+/H+ exchanger function and intracellular pH control in sepsis and cardiac injury models. Its isoform selectivity and robust workflow adaptability empower advanced mechanistic and translational research on endothelial dysfunction.

• Triiodothyronine (T3): Precision Modulator of Beige Adipocyt

  2026-04-27

  Explore Triiodothyronine (T3) as a high-purity reagent for dissecting thyroid hormone signaling and beige adipocyte thermogenesis. This article uniquely bridges SEMA3E-driven pathways, advanced assay design, and metabolic research innovation.

• Sunitinib: Multi-Targeted RTK Inhibitor Powering RCC Researc

  2026-04-26

  Sunitinib, an oral multi-targeted receptor tyrosine kinase inhibitor, underpins advanced workflows for apoptosis induction and angiogenesis inhibition in renal cell carcinoma research. Recent studies reveal metabolic targeting strategies can restore sunitinib sensitivity, enabling more robust tumor suppression and resistance reversal. Explore protocol optimization, troubleshooting, and real-world insights for maximizing Sunitinib's impact in cancer models.

• Azithromycin, Roxithromycin: Senolytic Activity in Human Fib

  2026-04-25

  This study identifies azithromycin and roxithromycin as a new class of senolytic agents that selectively eliminate senescent human fibroblasts without affecting non-senescent cells. Using established DNA-damage–induced senescence models and quantitative assays, the research sheds light on the metabolic and autophagic mechanisms underlying this specificity, offering new directions for therapeutic targeting of cellular senescence.

• Staurosporine in Quantitative Cell Death: Assay Innovation a

  2026-04-24

  Explore how Staurosporine, a broad-spectrum serine/threonine protein kinase inhibitor, is revolutionizing quantitative apoptosis research. This article delves into high-throughput assay design, protocol parameters, and comparative insights for advanced cancer research.

• Chrysin Enhances Sunitinib Sensitivity in Renal Cell Carcino

  2026-04-24

  This study reveals that chrysin, a natural flavonoid, significantly increases sunitinib sensitivity in renal cell carcinoma (RCC) by inducing ferroptosis through suppression of the PI3K/Akt/GPX4 pathway. These findings suggest a promising combinatorial strategy for overcoming sunitinib resistance in RCC research.

• Z-YVAD-FMK in Inflammasome and Ferroptosis Research: New Fro

  2026-04-23

  Explore how Z-YVAD-FMK, a caspase-1 inhibitor, uniquely advances inflammasome and programmed cell death studies, bridging apoptosis and emerging ferroptosis insights. Discover protocol essentials, reference-driven interpretation, and novel applications beyond prior reviews.

• Z-IETD-FMK: Mechanistic Precision for Translational Immunolo

  2026-04-23

  This article explores the mechanistic underpinnings and translational potential of Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone), a specific caspase-8 inhibitor, across apoptosis, T cell proliferation inhibition, and immune signaling. Integrating recent insights from chicken pyroptosis research, it guides translational researchers on leveraging Z-IETD-FMK for advanced disease modeling, immune cell activation assays, and therapeutic innovation.

• NF 340: A Selective P2Y11 Antagonist for Cancer & Immunology

  2026-04-22

  NF 340 stands out as a research-grade, highly selective P2Y11 antagonist, enabling precise modulation of purinergic GPCR signaling in cutting-edge cancer and immunology models. Applied protocols and troubleshooting strategies unlock new depth in inflammation pathway analysis and breast cancer invasion assays.

14937 records 1/996 page Next 12345 下5页 Last page